Monitoring of T-cell subsets in patients treated with anti-CD 25 antibody

Transplantation Proceedings

Volumn 36, Issue 2 SUPPL., 2004, Pages S487-S491

  Praditpornsilpa, K ^a   Avihingsanon, Y ^a   Kupatawintu, P ^a   Songpanich, S ^a   Pisitkul, T ^a   Kansanabuch, T ^a   Eiam Ong, S ^a   Chusil, S ^a   O Charoen, R ^a   Tungsanga, K ^a  

^a KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CD3 ANTIGEN; CYCLOSPORIN; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; PREDNISOLONE;

ANTIGEN EXPRESSION; ARTICLE; BIOLOGICAL MONITORING; BLOOD SAMPLING; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG MONITORING; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECEPTOR BLOCKING; T LYMPHOCYTE SUBPOPULATION;

EID: 12144290787     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.01.071     Document Type: Article

References (11)

1. Vincenti F., Kirkman R., Light S., et al. Interleukin-2-receptor blockage with Daclizumab to prevent acute rejection in renal transplantation. N Engl J Med. 338:1998;161.
2. Nashan B., Light S., Hardie I.R., et al. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation. 67:1999;110.
3. Nashan B., Moore R., Amlot P., et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet. 350:1997;1193.
4. Steiger J., Nickerson P.W., Steurer W., et al. IL-2 knockout recipient mice reject islet cell allografts. J Immunol. 155:1995;489.
5. Li X.C., Roy-Chaudhury P., Hancock W.W., et al. IL-2 and IL-4 double knockout mice reject islet allografts A role for novel T cell growth factors in allograft rejection. J Immunol. 161:1998;890.
6. Bumgardner G.L., Hardie I., Johnson R.W.G., et al. Results of 3-year phase III clinical trials with Daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation. 72:2001;839.
7. Vincenti F., Lantz M., Birnbaum J., et al. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. Transplantation. 63:1997;33.
8. Kovarik J.M., Rawlings E., Sweny P., et al. Pharmacokinetics and immunodynamics of chimeric IL-2 receptor monoclonal antibody SDZ CHI 621 in renal allograft recipients. Transpl Int. 9:(suppl 1):1996;S32.
9. Junghans R.P., Waldmann T.A., Landolfi N.F., et al. Anti-TAC, a humanized antibody to interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res. 50:1990;1495.
10. Kovarik J.M., Kahan B.D., Rajagopalan P.R., et al. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group. Transplantation. 68:1999;1288.
11. Bumgardner G.L., Ramos E., Lin A., et al. Daclizumab (humanized anti-IL-2Rα mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function. Transplantation. 72:2001;642.